CompletedPhase 4ACTRN12611000573954
Adjunctive Medical Therapy with Oral Silodosin after Shock Wave Lithotripsy of Lower Ureteral Stone: A randomized controlled study
The efficacy of adjunctive medical therapy with daily oral silodosin(4 mg) after Shock Wave Lithotripsy of lower ureteral stone
Sponsor
Chung Jing Wang
Enrollment
45 participants
Start Date
Jun 1, 2010
Study Type
Interventional
Conditions
Summary
a prospective study to evaluate the efficacy of oral silodosin 4 mg as adjunctive therapy after ESWL of lower ureteral stones
Eligibility
Sex: Both males and femalesMin Age: 20 YearssMax Age: 60 Yearss
Inclusion Criteria1
- Stones were calculated according to the diameter along the ureteral axis, and the size was between 4mm and 9 mm. All patients underwent ESWL were enrolled in the study after providing informed consent.
Exclusion Criteria1
- urinary tract infections, high-grade hydronephrosis, diabetes, ulcers, or a history of hypersensitivity to a-blockers, ureteral stricture and pregnant women,history of spontaneous stone expulsion, hypotension, or those found to have systolic blood pressure lower than 110 mmHg
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Daily oral 4 mg silodosin for 2 weeks as adjunctive therapy after ESWL of lower ureteral stones
Daily oral 4 mg silodosin for 2 weeks as adjunctive therapy after ESWL of lower ureteral stones
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000573954